Skip to main content
Premium Trial:

Request an Annual Quote

GSK to Integrate Procognia's Protein Kinase Arrays Into Drug Development

Premium
Two weeks after it sold an internally developed protein chip platform to GenTel Biosciences, GlaxoSmithKline agreed to couple certain of its kinase inhibitors with Procognia’s protein array platform, enabling Procognia to sell label-free kinase-screening arrays.
 
Procognia also announced that in coming weeks it will begin selling a product that contains all known human kinases and uses GSK's inhibitors.
 
According to Andy Sutcliffe, a sales development manager at Procognia, the agreement gives Procognia access to GSK's fluorescently labeled broad-specificity kinase inhibitors.
 
When the broad-specificity fluorescent ligands are attached to Procognia's existing protein arrays, it creates a product that can perform label-free kinase screening. It is this technology that Prognia said it plans to market.
 
"It means that if you then come in with [an] unlabeled molecule — say, your compound of interest — and you apply that to the array it will displace the fluorescent molecule,” Sutcliffe told ProteoMonitorsister publication BioArray News this week. “So this is actually a label-free technology."
 
"That's very applicable to companies like GSK that do a huge number of kinase-screening programs. It enables pharmaceutical companies to use these arrays in-house, rather than outsourcing their kinase screens," he said.
 
The first product available using the combined GSK-Procognia technology will be Procognia's human Kinome 2.0 Plus Compound Profiling Kit. The kit will include 336 proteins, 305 of which are human kinases with the rest comprising splice variants or kinase-associated proteins.
 
GSK will be an initial customer and will use Procognia's arrays in-house to profile its kinase hits. In addition, the companies will work together to assess where GSK may integrate Procognia’s protein array technology into its screening process, Sutcliffe said.
 
"This is a consumable item and will be produced as a catalog array for anyone to use," Sutcliffe said. "This collaboration is an R&D collaboration. Procognia can use GSK's broad-specificity fluorescent ligands which we can use within our products and which we can then sell to all of our customers around the world."
 
Procognia has been developing its kinase panel over the last 15 months, the company said in a statement.
 
The firm currently sells a glycoprotein array through a partnership with Qiagen, and produces pathway-specific human antibody chips through its collaboration with Sigma-Aldrich. Sigma also sells an earlier version of Procognia's kinase array as the Panorama Human Kinase Version 1 Array.
 
Pharma Eyeing Protein Arrays
 
GSK's decision to partner with Procognia comes as some vendors say pharmas are increasingly finding protein arrays attractive.
 
Also this week, George Mason University researchers Lance Liotta and Emanuel Petricoin launched a new company that plans to market a protein microarray technology they say will allow scientists to analyze the activity of proteins in tissue samples.
 
The company, they said, is negotiating with several undisclosed pharma companies that would use the technology to develop new cancer drugs [see related story, this issue].
 
Invitrogen has also been working closely with its pharmaceutical clients to upgrade its ProtoArray product. "We have seen an overall increase in interest from pharmaceutical and biotech companies to incorporate [our] technology platforms into their target identification and lead optimization processes," spokesperson Eric Endicott told BioArray News in an e-mail this week.
 
He said Invitrogen has recently collaborated with “two large pharmaceutical companies” in the areas of small-molecule protein profiling and kinase-inhibition assays using its ProtoArray protein microarray technology.
 
Invitrogen will be one of Procognia's main competitors in the market. Endicott claimed that the firm's Human ProtoArray contains the "highest kinome content commercially available with 378 full-length human kinases," and that the firm plans to add more kinases to future versions of its protein microarrays.
 

“The decision to select a preferred protein microarray service provider comes down to assay performance, specifically reproducibility, but more importantly is trust in the relationship and the flexibility or easiness to work well together.”

Procognia’s Sutcliffe said that the fact that its kinase arrays would be label-free would give it an advantage over competitors like Invitrogen. "For this product there are actually no direct competitors. There's no other company that does label-free kinase screening on protein arrays," he said.
 
Shedding One Protein-Array Asset, Partnering With Another
 
GSK's decision to partner with Procognia comes a few weeks after it sold an internally developed protein chip platform to GenTel Biosciences, a Madison, Wisc.-based protein array vendor [see PM 03/15/07]. 
 
As part of the deal, GenTel received from GSK personnel, instrumentation, intellectual property rights, and four multiplex immunoassays developed and validated at GSK: a chip for human cytokines, a chip for mouse cytokines, a metabolic chip, and a matrix metalloproteinase chip. GenTel currently does not offer a kinase chip.
 
GenTel also received GSK’s system of automation and robotic equipment, statistical and reporting tools, and software tools.
 
This week Robert Negm, GenTel’s vice president of business development said that GSK’s recent actions coincide with an increased “willingness of big pharma to purchase services from protein microarray companies” that has increased over the last three years.
 
Outsourcing to companies like GenTel or Procognia “demonstrates how drug developers prioritize delivering drugs to the market over initiatives to build cutting-edge life science tools,” Negm said. “The decision to select a preferred protein microarray service provider comes down to assay performance, specifically reproducibility, but more importantly is trust in the relationship and the flexbility or easiness to work well together.”
  
This original version of this article appears in the current issue of ProteoMonitor sister publication BioArray News.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.